NYSE:MNK

Mallinckrodt - MNK Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: N/A
50-Day Range: $0.14
▼
$0.75
52-Week Range: N/A

Volume: 290,539 shs
Average Volume: 6.49 million shs
Market Capitalization: $1.69 million

P/E Ratio: 0.00
Dividend Yield: N/A
Price Target: N/A

About Mallinckrodt (NYSE:MNK) Stock

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Receive MNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter.

MNK Stock News Headlines

September 29, 2022 | marketwatch.com

Endo Bankruptcy Judge Approves Rep for Future Opioid Victims - MarketWatch

September 21, 2022 | businesswire.com

Global Paracetamol IV Market Report 2022: Rising Cases of Postoperative Pain Fueling Growth - ResearchAndMarkets.com - Business Wire

September 15, 2022 | finance.yahoo.com

Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS) - Yahoo Finance

August 30, 2022 | streetinsider.com

Form N-PX PROFESSIONALLY MANAGED For: Jun 30 - StreetInsider.com

August 25, 2022 | finance.yahoo.com

Vitiligo Therapeutics Market - Information on Key Vendors Including (Alkem Laboratories Ltd., Bausch Health Companies Inc., Canixa Life Sciences, and more) - Yahoo Finance

August 17, 2022 | usnews.com

Endo Files for Bankruptcy as U.S. Opioid Litigation Drags - U.S. News & World Report

August 17, 2022 | washingtonpost.com

Analysis | Cortez Masto's misfired attack on Laxalt's opioid record - The Washington Post

August 4, 2022 | businesswire.com

U.S. Substance Abuse Treatment Market Research Report 2022: Surging Rate of Drug Addiction And the Growing Prevalence of Alcohol and Smoking Among U.S. Teenagers Driving Growth - ResearchAndMarkets.com - Business Wire

August 3, 2022 | businesswire.com

Healthcare Marketing Agency QooQoo Expands Project Management Team - Business Wire

August 1, 2022 | globenewswire.com

The Global Inhaled Nitric Oxide Market is expected to grow by $ 353.77 mn during 2022-2026, decelerating at a CAGR of 8.6% during the forecast period - GlobeNewswire

July 29, 2022 | businesswire.com

Healthcare Nanotechnology Global Market Research Report 2022 - ResearchAndMarkets.com - Business Wire

July 27, 2022 | washingtonpost.com

Opioid maker Teva agrees to tentative $4.25 billion deal - The Washington Post

July 21, 2022 | finance.yahoo.com

Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management - Yahoo Finance

July 14, 2022 | washingtonpost.com

Pulitzer Prize-winning reporters discuss their new book, “American Cartel,” with Alex Gibney - The Washington Post

July 12, 2022 | wsj.com

Endo Moving Toward Bankruptcy Filing Without Opioid Settlement Deal - The Wall Street Journal

June 28, 2022 | finance.yahoo.com

Morphine Market: Segmented: by application ; by Routine ;, And Region – Global Analysis Of Market Size, Share & Trends For 2019–2020 And Forecasts To 2031 - Yahoo Finance

June 23, 2022 | finance.yahoo.com

Mallinckrodt to Present Data on Terlipressin in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) 2022 International Liver Congress - Yahoo Finance

June 16, 2022 | bizjournals.com

How local corporations are stacking the C-suites of St. Louis startups - The Business Journals

June 6, 2022 | reuters.com

Mallinckrodt seeks expedited approval for scaled-back Chapter 11 exit financing - Reuters.com

May 30, 2022 | proactiveinvestors.com

Paradigm Biopharmaceuticals targets growth with appointment of US-based Marco Polizzi as CEO - Proactive Investors USA

May 27, 2022 | wsj.com

Mallinckrodt Bondholders to Finance Bankruptcy Exit After Market Snub - The Wall Street Journal

May 24, 2022 | finance.yahoo.com

NorthStar Medical Radioisotopes Enhances Management Team with Appointment of Monica Andersen as Vice President, Human Resources - Yahoo Finance

May 23, 2022 | cnn.com

January 6 felony defendant denied request to visit pharma company's 'boondoggle' in Cabo - CNN

April 21, 2022 | uk.finance.yahoo.com

Global Skin Burns Market Insight, Epidemiology and Market Forecast 2019-2032 Featuring Pfizer, Avita Medical, Mallinckrodt & RenovaCare - Yahoo Finance UK

March 11, 2022 | finance.yahoo.com

Colfax Announces Board of Directors for Enovis, the Post-Spinoff Medical Technology Company - Yahoo Finance

See More Headlines

Receive MNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter.

MNK Company Calendar

Last Earnings: 8/04/2020
Today: 10/01/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:MNK
CUSIP: N/A
CIK: 1567892
Web: www.mallinckrodt.com
Phone: (531) 696-0000
Fax: N/A
Employees: 3,400
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $8.88
Trailing P/E Ratio: 0.00
Forward P/E Ratio: N/A
P/E Growth: 0.01
Net Income: $-996,500,000.00
Net Margins: -89.94%
Pretax Margin: N/A
Return on Equity: 34.26%
Return on Assets: 6.66%

Debt

Debt-to-Equity Ratio: 5.39
Current Ratio: 1.48
Quick Ratio: 1.23

Sales & Book Value

Annual Sales: $3.16 billion
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 0.05
Book Value: $23.08 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 84,589,000
Free Float: N/A
Market Cap: $1.69 million
Optionable: Optionable
Beta: 3.06

Key Executives

Mark C. Trudeau
President, Chief Executive Officer & Director

Bryan M. Reasons
Chief Financial Officer & Executive Vice President

Steven Joseph Romano
Chief Scientific Officer & Executive VP

Babatunde Adekunle Otulana
Chief Medical Officer & Senior Vice President

Michele Robertson
Chief Compliance Officer & Senior Vice President

Key Competitors

View All Competitors

MNK Stock - Frequently Asked Questions

How were Mallinckrodt's earnings last quarter?: Mallinckrodt plc (NYSE:MNK) announced its earnings results on Tuesday, August, 4th. The company reported $1.89 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.55. The business earned $700.90 million during the quarter, compared to analysts' expectations of $630.19 million. Mallinckrodt had a negative net margin of 89.94% and a positive trailing twelve-month return on equity of 34.26%. The firm's revenue was down 14.9% on a year-over-year basis. During the same period in the prior year, the company earned $2.53 earnings per share.
Read the conference call transcript.
What other stocks do shareholders of Mallinckrodt own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), Advanced Micro Devices (AMD).

What is Mallinckrodt's stock symbol?: Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How much money does Mallinckrodt make?: Mallinckrodt (NYSE:MNK) has a market capitalization of $0.00 and generates $3.16 billion in revenue each year. The company earns $-996,500,000.00 in net income (profit) each year or $8.88 on an earnings per share basis.
How many employees does Mallinckrodt have?: The company employs 3,400 workers across the globe.
How can I contact Mallinckrodt?: Mallinckrodt's mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The official website for the company is www.mallinckrodt.com. The company can be reached via phone at (531) 696-0000 or via email at investor.relations@mnk.com.

This page (NYSE:MNK) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms